|Title:||Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study||Authors:||Heerspink, Hiddo J L
Wilding, John P H
Garcia Rodriguez, Luis Alberto
|Issue Date:||Jan-2020||Journal Volume:||8||Journal Issue:||1||Source:||The lancet. Diabetes & endocrinology||Abstract:||
Cardiovascular and kidney outcome trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with type 2 diabetes with or without chronic kidney disease. The aim of this study was to assess whether these benefits extend to patients with type 2 diabetes treated in routine clinical practice.
|Appears in Collections:||臨床藥學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.